Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.

Sci Transl Med. 2019 Jul 31;11(503). pii: eaaw4993. doi: 10.1126/scitranslmed.aaw4993.

2.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130:4492-4505. doi: 10.1172/JCI128212.

3.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print]

PMID:
31227306
4.

Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.

Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM.

Nat Cell Biol. 2019 Feb;21(2):238-250. doi: 10.1038/s41556-018-0267-0. Epub 2019 Jan 21.

PMID:
30664790
5.

The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells.

Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, Reed MJ, Nelson PS.

Mol Cancer Res. 2019 Jan;17(1):321-331. doi: 10.1158/1541-7786.MCR-18-0522. Epub 2018 Sep 17.

PMID:
30224545
6.

A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.

Mamouni K, Zhang S, Li X, Chen Y, Yang Y, Kim J, Bartlett MG, Coleman IM, Nelson PS, Kucuk O, Wu D.

Neoplasia. 2018 Aug;20(8):789-799. doi: 10.1016/j.neo.2018.06.003. Epub 2018 Jul 4.

7.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

8.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG.

Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.

9.

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.

Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.

10.

Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Bianchi-Frias D, Basom R, Delrow JJ, Coleman IM, Dakhova O, Qu X, Fang M, Franco OE, Ericson NG, Bielas JH, Hayward SW, True L, Morrissey C, Brown L, Bhowmick NA, Rowley D, Ittmann M, Nelson PS.

Mol Cancer Res. 2016 Apr;14(4):374-84. doi: 10.1158/1541-7786.MCR-15-0330. Epub 2016 Jan 11.

11.

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.

Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C.

Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12.

12.

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2. Epub 2013 Nov 17.

13.

VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman IM, Nelson PS, Vessella RL, Davis RJ, Plymate SR, Mercurio AM.

Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9.

14.

Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS.

Am J Pathol. 2011 Jul;179(1):400-10. doi: 10.1016/j.ajpath.2011.03.028. Epub 2011 May 4.

15.

EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.

Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LW, Zhau HE, Wu D.

Oncogene. 2011 Dec 15;30(50):4941-52. doi: 10.1038/onc.2011.199. Epub 2011 May 30.

16.

The effects of aging on the molecular and cellular composition of the prostate microenvironment.

Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS.

PLoS One. 2010 Sep 1;5(9). pii: e12501. doi: 10.1371/journal.pone.0012501.

17.

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR.

J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.

18.

Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.

Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS.

Cancer Res. 2010 Feb 15;70(4):1286-95. doi: 10.1158/0008-5472.CAN-09-2509. Epub 2010 Feb 2.

19.

The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.

Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL.

Prostate. 2010 Mar 1;70(4):412-24. doi: 10.1002/pros.21075.

20.

Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.

Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ.

Cancer Res. 2009 Oct 1;69(19):7793-802. doi: 10.1158/0008-5472.CAN-08-3810. Epub 2009 Sep 22.

21.

Prostate cancer-associated gene expression alterations determined from needle biopsies.

Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM.

Clin Cancer Res. 2009 May 1;15(9):3135-42. doi: 10.1158/1078-0432.CCR-08-1982. Epub 2009 Apr 14.

22.

Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.

Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW.

Cancer Res. 2008 Dec 1;68(23):9996-10003. doi: 10.1158/0008-5472.CAN-08-2492.

23.

Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.

Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA.

Prostate. 2009 Jan 1;69(1):1-11. doi: 10.1002/pros.20854.

24.

Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate.

Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY.

BMC Genomics. 2008 May 23;9:246. doi: 10.1186/1471-2164-9-246.

25.

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL.

Clin Exp Metastasis. 2008;25(4):377-88. Epub 2007 Oct 31.

PMID:
17972146
26.

Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues.

Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2150-4.

27.

Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.

Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS.

Prostate. 2007 Nov 1;67(15):1621-9.

PMID:
17823924
28.

Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression.

He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW.

Cancer Res. 2007 Sep 1;67(17):8188-97.

29.

Genetic background influences murine prostate gene expression: implications for cancer phenotypes.

Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS.

Genome Biol. 2007;8(6):R117.

30.

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS.

Cancer Res. 2007 May 15;67(10):5033-41.

31.

Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey E.

Neoplasia. 2006 Oct;8(10):862-78.

32.

Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.

Lin DW, Coleman IM, Hawley S, Huang CY, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, Nelson PS.

J Clin Oncol. 2006 Aug 10;24(23):3763-70. Epub 2006 Jul 5. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334. Huang, Chung Y [added].

PMID:
16822846
33.

Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE.

Am J Pathol. 2005 Jul;167(1):255-66.

34.

Optimized T7 amplification system for microarray analysis.

Pabón C, Modrusan Z, Ruvolo MV, Coleman IM, Daniel S, Yue H, Arnold LJ Jr.

Biotechniques. 2001 Oct;31(4):874-9.

Supplemental Content

Loading ...
Support Center